.jetcityimage/iStock Editorial using Getty Images Morgan Stanley has actually opted for Eli Lilly (NYSE: LLY) as its best biopharma choice for 2025 as well as rated another 9 labels in the area as obese. The investment banking company stated in a note that it remains to feel “diabesity is readied to end up being.